|
211 |
Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. |
Xavier D, Pais P, Devereaux PJ, Xie C, Prabhakaran D, Reddy KS, Gupta R, Joshi P, Kerkar P, Thanikachalam S, Haridas KK, Jaison TM, Naik S, Maity AK, Yusuf S; CREATE registry investigators. |
Lancet. |
2008 |
|
212 |
Randomized trials in vulnerable populations. |
Cook D, Moore-Cox A, Xavier D, Lauzier F, Roberts I. |
Clin Trials. |
2008 |
|
213 |
Effects of extended-release metoprolol succinate in patients undergoing non-cardiac surgery (POISE trial): a randomised controlled trial. |
Devereaux PJ, Yang H, Yusuf S, Xavier D, Pais P, et al. |
Lancet. |
2008 |
|
214 |
Lipids, lipoproteins, and apolipoproteins as risk markers of myocardial infarction in 52 countries (the INTERHEART study): a case-control study. |
McQueen MJ, Hawken S, Wang X, Ounpuu S, Sniderman A, Kazmi K, Yusuf S, et al; |
Lancet 2008. |
2008 |
|
215 |
VITATOPS, the VITAmins TO prevent stroke trial: rationale and design of randomised trial of B-vitamin therapy in patients with recent transient ischaemic attack or stroke. |
VITATOPS Trial Study Group; Hankey GJ, Algra A, Chen C, Wong MC, Cheung R, Xavier D, et al. |
Int J Stroke |
2007 |
|
216 |
Glucose-insulin potassium therapy in patients with ST-segment elevation myocardial infarction. |
Díaz R, Goyal A, Xavier D, et al; |
JAMA. |
2007 |
|
217 |
Rationale, design and baseline data of a randomized, double-blind, controlled trial comparing two antithrombotic regimens (fixed-dose combination of extended-release dipyridamole plus ASA with clopidogrel) and telmisartan versus placebo in stroke patients |
Diener HC, Sacco R, Yusuf S; Steering Committee; PRoFESS Study Group. |
Cerebrovasc Dis |
2007 |
|
218 |
Perspectives on the management of coronary artery disease in India. |
Karthikeyan G, Xavier D, Prabhakaran D, Pais P. |
Heart |
2007 |
|
219 |
Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the OASIS-6 randomized trial. |
Yusuf S, Mehta SR, Chrolavicius S, Afzal R, et al; |
JAMA |
2006 |
|
220 |
Rationale, design, and organization of the PeriOperative ISchemic Evaluation (POISE) trial: a randomized controlled trial of metoprolol versus placebo in patients undergoing noncardiac surgery. |
Devereaux PJ, Yang H, Guyatt GH, Pais P, Xavier D, Yusuf S, et al. |
Am Heart J |
2006 |
|
221 |
Tobacco use and risk of myocardial infarction in 52 countries in the INTERHEART study: a case-control study. |
Teo KK, Ounpuu S, Hawken S, Pandey MR, Yusuf S, et al; |
Lancet 2006 |
2006 |
|
222 |
Design and rationale of the MICHELANGELO Organization to Assess Strategies in Acute Ischemic Syndromes (OASIS)-5 trial program evaluating fondaparinux, a synthetic factor Xa inhibitor, in patients with non-ST-segment elevation acute coronary syndromes. |
MICHELANGELO OASIS 5 Steering Committee, Mehta SR, Yusuf S, et al; |
Am Heart J |
2005 |
|
223 |
Obesity and the risk of myocardial infarction in 27,000 participants from 52 countries: a case-control study. |
Yusuf S, Hawken S, Ounpuu S, et al; |
Lancet. |
2005 |
|
224 |
Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. |
Yusuf S, Mehta SR, Xavier D, Pais P, Zhu J, Liu L, et al; |
JAMA |
2005 |
|
225 |
Effect of glucose-insulin-potassium infusion on mortality in patients with acute ST-segment elevation myocardial infarction: the CREATE-ECLA randomized controlled trial. |
Mehta SR, Yusuf S, Díaz R, Zhu J, Pais P, Xavier D, et al; |
JAMA |
2005 |